Skip to content
Screener

Bicara Therapeutics BCAX Price / book

Price / book at other companies

Eli Lilly logo
Eli LillyLLY
31.6×-6.7×
Amgen logo
AmgenAMGN
16.7×-3.4×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
3.1×0.0×
Arcus Biosciences logo
Arcus BiosciencesRCUS
8.4×+6.7×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
143.7×+142×
Immunome logo
ImmunomeIMNM
4.2×+2.3×

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.81B+217%
Enterprise value$1.49B+1,000%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Calculated from Bicara Therapeutics’s reported figures.

market cap/total stockholders equity=2.5×

Based on the most recent quarter.

The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026. Open the filing →

Filed
May 11, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033429

FAQ

What is Bicara Therapeutics's price / book?
Bicara Therapeutics (BCAX) reported price / book of 2.5× in Q1 2026.
How has Bicara Therapeutics's price / book changed year-over-year?
Bicara Therapeutics's price / book increased by 62.0% year-over-year, from 1.5× to 2.5×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Bicara Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude